Use and Safety of Immunotherapeutic Management of N-Methyl-D-Aspartate Receptor Antibody Encephalitis A Meta-analysis

Creative Commons License

Nosadini M., Eyre M., Molteni E., Thomas T., Irani S. R., Dalmau J., ...More

JAMA NEUROLOGY, vol.78, no.11, pp.1333-1344, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 78 Issue: 11
  • Publication Date: 2021
  • Doi Number: 10.1001/jamaneurol.2021.3188
  • Journal Name: JAMA NEUROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Psycinfo
  • Page Numbers: pp.1333-1344
  • Hacettepe University Affiliated: No


IMPORTANCE Overall, immunotherapy has been shown to improve outcomes and reduce relapses in individuals with N-methyl-D-aspartate receptor (NMDAR) antibody encephalitis (NMDARE); however, the superiority of specific treatments and combinations remains unclear.